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Prostate Size Correlates with Fasting Blood Glucose in Non-
Diabetic Benign Prostatic Hyperplasia Patients with Normal 
Testosterone Levels 
We evaluated the correlations between BMI, fasting glucose, insulin, testosterone level, 
insulin resistance, and prostate size in non-diabetic benign prostatic hyperplasia (BPH) 
patients with normal testosterone levels. Data from 212 non-diabetic BPH patients with 
normal testosterone levels, who underwent transurethral resection of the prostate (TURP) 
due to medical treatment failure, were evaluated retrospectively. Patients with prostate 
specific antigen (PSA) levels of ≥ 3 ng/mL underwent multicore transrectal prostate biopsy 
before TURP to rule out prostate cancer. Patients with diabetes mellitus (DM) or serum 
testosterone levels of < 3.50 ng/mL were excluded from analysis. Correlations between 
clinical and laboratory parameters were determined. Prostate size correlated positively with 
age (r = 0.227, P < 0.001), PSA (r = 0.510, P < 0.001), and fasting glucose level (r = 0.186, 
P = 0.007), but not with BMI, testosterone, insulin level, or insulin resistance (each P > 0.05). 
Testosterone level inversely correlated with BMI (r = -0.327, P < 0.001), insulin level (r = 
-0.207, P = 0.003), and insulin resistance (r = -0.221, P = 0.001), but not with age, 
prostate size, PSA, or fasting glucose level (each P > 0.05). Upon multiple adjusted linear 
regression analysis, prostate size correlated with elevated PSA (P < 0.001) and increased 
fasting glucose levels (P = 0.023). In non-DM BPH patients with normal testosterone levels, 
fasting glucose level is an independent risk factor for prostate hyperplasia.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is the most common pros-
tate disease, characterized by nonmalignant enlargement of 
the prostate gland in aging men. The prevalence of BPH rises 
with age (1). Although the exact pathogenesis of BPH is far from 
completely understood, aging, testosterone levels, clinically sig-
nificant lower urinary tract symptoms, inflammation, alteration 
in cell signaling are the significant risk factors for the develop-
ment of BPH (2, 3). In addition, insulin, insulin-like growth fac-
tors (IGFs), diabetes mellitus (DM), and obesity are known an-
drogen-independent risk factors in BPH development (4).
 Testosterone is the main circulating androgen in adult males 
and is secreted primarily by the testis. It also promotes prostate 
growth by increasing the ratio of cellular proliferation to death. 
Testosterones and growth factors regulate this ratio by both stim-
ulating proliferation and inhibiting apoptosis (5). Dihydrotestos-
terone (DHT), a derivative of testosterone, modulates the effects 
of several growth factors involved in BPH development, includ-
ing fibroblast growth factors (FGFs), vascular endothelial growth 
factors (VEGFs), and IGFs (5-8). 
 In particular, IGFs are regarded as potent inducers of prostate 
growth in vitro (9, 10), and insulin levels, obesity and DM are 
considered risk factors for BPH development (11, 12). These fac-
tors are associated with a metabolic syndrome characterized by 
insulin resistance and hyperinsulinemia. Two main components 
of the metabolic syndrome are obesity and abnormal glucose 
homeostasis (13). Vikram et al. (14) demonstrated that a high-fat 
diet resulting in hyperinsulinemia led to increased cellular pro-
liferation and enlargement of the prostate in rats. Also, Nandee-
sha et al. (15) reported that hyperinsulinemia associated with 
insulin resistance was an independent risk factor for the devel-
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opment of BPH in non-DM men. Therefore, insulin resistance 
and hyperinsulinemia play a significant role in the BPH devel-
opment. However, in non-DM BPH patients with normal testos-
terone levels, the relationships between body mass index (BMI), 
insulin level, insulin resistance and prostate growth have not 
been yet established. This study evaluated these relationships 
in non-diabetic BPH patients with normal testosterone levels 
who underwent transurethral resection of the prostate (TURP).  
MATERIALS AND METHODS
Patient characteristics
Clinical data from 345 BPH patients who underwent TURP was 
reviewed retrospectively. From July 1996 to February 2010, pa-
tients whose serum was taken on the morning of the operation 
day among patients underwent TURP were enrolled. To rule out 
prostate cancer, patients whose prostate specific antigen (PSA) 
levels were greater than or equal to 3 ng/mL were subjected to 
multicore transrectal prostate biopsy (generally 12 cores) before 
TURP. Prostate size was measured by transrectal ultrasound and 
the volume was calculated from transverse images by using the 
prolate-ellipsoid formula (0.524 × height × width × length) (16). 
Patients on medical treatment for DM were excluded, as were 
patients whose serum testosterone levels were less than 3.50 ng/ 
mL, or who had been placed on any testosterone replacement 
medications such as testosterone injection or testosterone gel 
that could affect testosterone levels. Altogether, 212 BPH patients 
without DM and with normal testosterone levels were included 
in the analysis. 
Laboratory tests
On the morning of the operation day, patient’s serum was taken. 
Serum PSA levels were measured by using a quantified mono-
clonal IRMA radioimmunoassay (Izotop, Budapest, Hungary). 
Glucose levels were measured on a Hitachi 7600 automatic 
chemical analyzer (Hitachi, Tokyo, Japan) using the hexokinase 
method. Insulin and testosterone levels were measured by us-
ing an Elecsys 2010 autoanalyzer (Roche Diagnostics, Indianap-
olis, IN, USA) according to electrochemiluminescence immu-
noassay principles. Insulin levels were measured by a method 
that employs insulin-specific monoclonal antibodies and is 
based on the sandwich test principle. The testosterone assay 
was based on the competitive test principle and employed a 
polyclonal testosterone-specific antibody. All assays were per-
formed according to the manufacturers’ instructions. Insulin 
resistance was determined by the homeostasis model assess-
ment (HOMA) using the following formula (17): 
HOMA =
    (fasting glucose × fasting insulin)   
                              22.5 × 18
Statistical analysis
Correlations between prostate size, testosterone level, insulin 
resistance, and other clinico-laboratory parameters (age, height, 
weight, BMI, PSA, fasting glucose, and insulin levels) were as-
sessed. In addition, multiple linear regression analysis was per-
formed to evaluate the association between prostate size and 
other parameters. Statistical analyses were performed by the Sta-
tistical Package for Social Sciences, version 12.0, software (SPSS 
Inc., Chicago, IL, USA). All tests were performed using a 2-tailed 
analysis, and a P value of < 0.05 was considered statistically sig-
nificant.
Ethics statement
The collection and analysis of all samples was approved by the 
institutional review board of Chungbuk National University Hos-
pital (Cheongju, Korea; IRB registration number 2006-01-001). 
An informed consent was obtained from each patient.
 
RESULTS
Baseline characteristics
The mean age of the study population was 68.81 ± 7.14 yr and 
the mean BMI was 23.56 ± 3.14 kg/m2. The mean serum PSA, 
testosterone, fasting glucose, and insulin levels were 4.14 ± 3.82 
ng/mL, 6.00 ± 2.11 ng/mL, 93.89 ± 18.49 mg/dL, and 9.51 ± 10.97 
mg/dL, respectively. The mean HOMA-IR and prostate size were 
2.26 ± 2.73 and 44.08 ± 24.76 g. Additional baseline characteristics 
of the patients included in this study are presented in Table 1. 
Correlations among prostate size, testosterone, HOMA-IR, 
and clinico-laboratory parameters 
As shown in Table 2, prostate size positively correlated with age 
(r = 0.227, P < 0.001), PSA (r = 0.510, P < 0.001), and fasting glu-
cose (r = 0.186, P = 0.007), but not with BMI, testosterone, insu-
lin level, or HOMA-IR. Testosterone level inversely correlated 
with BMI (r = -0.327, P < 0.001), insulin level (r = -0.207, P = 0.003), 
and HOMA-IR (r = -0.221, P = 0.001), but not with age, prostate 
Table 1. Baseline characteristics of the BPH patients without DM and with normal 
testosterone levels 
Parameters   Mean ± standard deviation
Age (yr)   68.81 ± 7.14
Height (cm) 164.12 ± 6.02
Weight (kg)   63.52 ± 9.57
BMI (kg/m2)   23.56 ± 3.14
PSA (ng/mL)     4.14 ± 3.82
Prostate size (g)     44.08 ± 24.76
Testosterone (ng/mL)     6.00 ± 2.11
Fasting glucose (mg/dL)     93.89 ± 18.49
Insulin (mg/dL)       9.51 ± 10.97
HOMA-IR     2.26 ± 2.73
BMI, body mass index; PSA, prostate-specific antigen; HOMA, homeostasis model 
assessment; IR, insulin resistance.
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size, PSA, or fasting glucose. HOMA-IR significantly correlated 
with BMI (r = 0.328, P < 0.001), fasting glucose (r = 0.263, P < 
0.001), and insulin level (r = 0.975, P < 0.001), but not with age, 
PSA, or prostate size. 
Multiple linear regression analysis of the associations 
between prostate size and other clinico-laboratory 
parameters
As shown in Table 3, in multiple adjusted linear regression anal-
ysis, prostate size was significantly associated with PSA (P < 0.001) 
and fasting glucose level (P = 0.023). However, prostate size was 
not related to age, BMI, testosterone, insulin level, or HOMA-IR.
DISCUSSION
In this study, several well-known risk factors for the develop-
ment of BPH were evaluated in BPH patients with normal tes-
tosterone levels and no evidence of DM. Fasting glucose level 
was the only independent risk factor for prostatic hyperplasia 
in these patients. Other factors, including obesity, hyperinsu-
linemia, and insulin resistance, were not significantly associat-
ed with prostate size. 
 Many previous studies have demonstrated that obesity, DM, 
high insulin, and low HDL cholesterol are risk factors for the de-
velopment of BPH (12, 14, 15). It is likely that obesity promotes 
BPH by inducing systemic inflammation and oxidative stress 
(18). Inflammatory mediators and oxidative stress could possi-
bly promote unregulated prostate growth through a nonmalig-
nant pathway (19, 20). It is also possible that alterations in the 
balance between testosterone and estrogen levels in prostate 
tissue contribute to BPH development (21), because increased 
adipose tissue promotes increased aromatization of circulating 
testosterone into estrogen (22). However, in the current study of 
non-DM BPH patients with normal testosterone levels, BMI was 
not correlated with prostate size. In our previous study (23), the 
positive correlation between BMI and prostate size in patholog-
ically proven BPH patients might be due to the inclusion of pa-
tients with DM and low testosterone levels. These findings sug-
gest that obesity may not be an independent risk factor for the 
development of BPH in non-DM patients with normal testos-
terone levels. 
 Insulin resistance, a condition in which a normal level of in-
sulin elicits a subnormal response, is associated with a group of 
disorders such as obesity, dyslipidemia, elevated fasting glucose 
levels, hyperinsulinemia, and hypertension (4). Recent experi-
mental animal studies showed that hyperinsulinemia led to in-
creased cellular proliferation and enlargement of the prostate 
in rats (14). In addition, several studies have shown that insulin-
resistance and hyperinsulinemia could be independent risk fac-
tors for BPH (15, 24). In the present study, there was no correla-
tion between insulin level, or insulin resistance and prostate 
size. Vikram et al. (4) suggested that prostate growth by hyper-
insulinemia could be attributed to the 1) enhanced mitogenic 
activity of insulin; 2) altered steroidal hormonal activity; 3) in-
creased sympathetic tone; or 4) perturbed endocrine levels in 
the prostate. However, in the current study of non-DM BPH pa-
tients with normal testosterone levels, no relationship between 
prostate growth and the above-mentioned metabolic factors 
was observed. 
 Although normal prostate growth is known to be testosterone-
Table 2. Correlations between prostate size, testosterone, HOMA-IR, and other clinical and laboratory parameters
Parameters
Prostate size Testosterone HOMA-IR
Correlation (r ) P value Correlation (r ) P value Correlation (r ) P value
Age (yr) 0.227 0.001 0.061 0.377 -0.028 0.689
Height (cm) 0.248 0.002 0.095 0.235 0.082 0.309
Weight (kg) 0.200 0.012 -0.261 0.001 0.331 < 0.001
BMI (kg/m2) 0.082 0.310 -0.327 < 0.001 0.328 < 0.001
PSA (ng/mL) 0.510 < 0.001 -0.091 0.195 0.037 0.597
Prostate size (g) - - -0.078 0.260 0.120 0.081
Testosterone (ng/mL) -0.078 0.260 - - -0.221 0.001
Fasting glucose (mg/dL) 0.186 0.007 -0.104 0.133 0.263 < 0.001
Insulin (mg/dL) 0.082 0.235 -0.207 0.003 0.975 < 0.001
HOMA-IR 0.120 0.081 -0.221 0.001 - -
BMI, body mass index; PSA, prostate-specific antigen; HOMA, homeostasis model assessment; IR, insulin resistance.
Table 3. Multiple linear regression analysis of the correlation between prostate size 
and other clinical and laboratory parameters
Parameters Estimate (β)
Standardized  
coefficients
P value
Age (yr) 0.429 0.125 0.087
Height (cm) -0.564 -0.138 0.738
Weight (kg) 1.692 0.658 0.423
BMI (kg/m2) -3.250 -0.422 0.570
PSA (ng/mL) 3.809 0.572 < 0.001
Testosterone (ng/mL) -0.143 -0.012 0.867
Fasting glucose (mg/dL) 0.285 0.215 0.023
Insulin (mg/dL) 0.491 0.230 0.601
HOMA-IR -2.081 -0.243 0.591
BMI, body mass index; PSA, prostate-specific antigen; HOMA, homeostasis model as-
sessment; IR, insulin resistance.
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dependent, higher testosterone levels do not necessarily result 
in enhanced prostate growth (25). For example, in hypogonadal 
men, testosterone replacement increased PSA and prostate size, 
mainly during the first 6 months of therapy, to levels equivalent 
to those of men without hypogonadism but no higher (26). Fur-
thermore, within the range of normal testosterone levels, there 
is no clear relationship between the concentration of circulating 
testosterone and prostate size in aging males (27). In this study, 
there was no correlation between testosterone level and prostate 
size in non-DM BPH patients with normal testosterone levels.
 Low testosterone levels may predispose males to visceral obe-
sity, which leads to the dysregulation of fatty acid metabolism, 
which in turn promotes insulin resistance (28). Testosterone in-
hibits lipoprotein lipase activity in abdominal adipose tissue, 
which leads to decreased triglyceride uptake in central fat de-
pots (29). Pitteloud et al. (30) reported that low serum testoster-
one levels were associated with an adverse metabolic profile and 
that low testosterone levels promoted insulin resistance in men. 
They also reported that serum testosterone levels were positive-
ly related to insulin sensitivity (30); nevertheless, it does not nec-
essarily follow that serum testosterone levels are inversely asso-
ciated with insulin resistance. In the current study, serum testos-
terone levels were inversely correlated with BMI, insulin level, 
and HOMA-IR. In addition, because low testosterone levels are 
a consequence of the dysregulation of fatty acid metabolism and 
BPH patients with low testosterone were excluded, patients with 
insulin resistance due to the dysregulation of fatty acid metabo-
lism were not evaluated within this study. Thus, metabolic dys-
regulation does not contribute to prostate growth in non-DM 
BPH patients with normal testosterone levels.
 In the present study, multiple regression analysis revealed that 
serum fasting glucose levels correlated positively with prostate 
size. Parsons et al. (12) reported that obesity, elevated fasting glu-
cose and diabetes were risk factors for BPH. In their study of 422 
men, obesity and DM as well as fasting glucose were related to 
prostate size. However, that study included patients with diabe-
tes and/or low testosterone levels. Altogether, these findings sug-
gest that other unknown factors may influence prostate growth 
in non-DM patients with normal testosterone levels through 
mechanisms other than testosterone, obesity, or abnormal glu-
cose homeostasis. Furthermore, lowering fasting glucose levels 
by drug and exercise might decrease prostate size and reduce 
the need for TURP in these patients. 
 In conclusion, this study is the first to examine the relation-
ships between BMI, insulin levels, insulin resistance, and pros-
tate size in non-DM BPH patients with normal testosterone lev-
els. In non-DM BPH patients with normal testosterone levels, 
prostate size correlated with fasting glucose levels but not with 
BMI, testosterone levels, insulin levels, or insulin resistance. 
Therefore, in these patients, fasting glucose level is an indepen-
dent risk factor for prostate hyperplasia. Consequently, further 
studies examining the relationship between BMI, insulin resis-
tance and prostate growth in different races are warranted, along 
with prospective, population-based studies in healthy individu-
als to evaluate the relationship between fasting blood glucose 
levels and the risk of developing BPH. 
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